(51) International Patent Classification:
A61K 31/55 (2006.01) C07D 233/10 (2006.01)
A61P 29/00 (2006.01)

(21) International Application Number:
PCT/GB05/003133

(22) International Filing Date: 10 August 2005 (10.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0417863.8 11 August 2004 (11.08.2004) GB

(71) Applicant (for all designated States except US): Cambridge University Technical Services Limited [GB/GB]; The Old Schools, Trinity Lane, Cambridge CB2 1TS (GB).

(72) Inventors; and

(75) Inventions/Applicants (for US only): GRAINGER, David, John [GB/GB]; Department of Medicine, Cambridge University, Box 157, Addenbrookes Hospital, Hill Road, Cambridge CB2 2QQ (GB). FOX, David, John [GB/GB]; Department of Chemistry, Cambridge University, Lensfield Road, Cambridge CB1 1EW (GB).

(74) Agent: DAVIES, Jonathan, Mark; Reddie & Grose, 16 Theobalds Road, London WC1 8PL (GB).

(54) Title: ANTI-INFLAMMATORY AGENTS

(57) Abstract: The invention provides compounds, compositions and uses of compounds of general formula (I) or pharmaceutically acceptable salts thereof, which are 3-aminocapro lactam derivatives, for the preparation of a medicament intended to treat an inflammatory disorder wherein X is -CO-Y-(R'), or SO₂-Y-(R')₂; and Y is 0 cycloalkyl or polycycloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group); or is 0 cycloalkenyl or polycycloalkenyl group.

\[
\text{(I)} \quad \text{X} \quad \text{N} \quad \text{O} \quad \text{NH}
\]
Anti-Inflammatory Agents

The invention relates to the use of 3-aminocapro lactam derivatives for preparing a medicament intended to prevent or treat inflammatory disorders.

Inflammation is an important component of physiological host defence. Increasingly, however, it is clear that temporally or spatially inappropriate inflammatory responses play a part in a wide range of diseases, including those with an obvious leukocyte component (such as autoimmune diseases, asthma or atherosclerosis) but also in diseases that have not traditionally been considered to involve leukocytes (such as osteoporosis or Alzheimer's disease).

The chemokines are a large family of signalling molecules with homology to interleukin-8 which have been implicated in regulating leukocyte trafficking both in physiological and pathological conditions. With more than fifty ligands and twenty receptors involved in chemokine signalling, the system has the requisite information density to address leukocytes through the complex immune regulatory processes from the bone marrow, to the periphery, then back through secondary lymphoid organs. However, this complexity of the chemokine system has at first hindered pharmacological approaches to modulating inflammatory responses through chemokine receptor blockade. It has proved difficult to determine which chemokine receptor(s) should be inhibited to produce therapeutic benefit in a given inflammatory disease.

More recently, a family of agents which block signalling by a wide range of chemokines simultaneously has been described: Reckless et al., Biochem J. (1999) 340:803-811. The first such agent, a peptide termed “Peptide 3”, was found to inhibit leukocyte migration induced by 5 different chemokines, while leaving migration in response to other chemoattractants (such as fMLP or TGF-beta) unaltered. This peptide, and its analogs such as NR58-3.14.3 (i.e. Sequence ID No.1 c(DCys-DGln-Dlle-DTrp-DLys-DGln-DLys-DPro-DAsp-DLeu-DCys)-NH2), are collectively termed “Broad Spectrum Chemokine Inhibitors” (BSCIs). Grainger et al., Biochem. Pharm. 65 (2003) 1027-1034 have subsequently shown BSCIs to have potentially useful anti-inflammatory activity in a range of animal models of diseases. Interestingly, simultaneous blockade of multiple chemokines is not apparently associated with acute or chronic toxicity, suggesting this
approach may be a useful strategy for developing new anti-inflammatory medications with similar benefits to steroids but with reduced side-effects.

However, peptides and peptoid derivatives such as NR58-3.14.3, may not be optimal for use in vivo. They are quite expensive to synthesise and have relatively unfavourable pharmacokinetic and pharmacodynamic properties. For example, NR58-3.14.3 is not orally bioavailable and is cleared from blood plasma with a half-life period of less than 30 minutes after intravenous injection.

Two parallel strategies have been adopted to identify novel preparations which retain the anti-inflammatory properties of peptide 3 and NR58-3.14.3, but have improved characteristics for use as pharmaceuticals. Firstly, a series of peptide analogs have been developed, some of which have longer plasma half-lives than NR58-3.14.3 and which are considerably cheaper to synthesise. Secondly, a detailed structure: activity analysis of the peptides has been carried out to identify the key pharmacophores and design small non-peptidic structures which retain the beneficial properties of the original peptide.

This second approach yielded several structurally distinct series of compounds which retained the anti-inflammatory properties of the peptides, including 16-amino and 16-aminoalkyl derivatives of the alkaloid yohimbine, as well as a range of N-substituted 3-aminoglutarimides. (Reference: Fox et al., J Med Chem 45(2002) 360-370: WO 99/12968 and WO 00/42071.) All of these compounds are broad-spectrum chemokine inhibitors which retain selectivity over non-chemokine chemotactants, and a number of them have been shown to block acute inflammation in vivo.

The most potent and selective of these compounds was (S)-3-(undec-10-enoyl)-aminoglutarimide (NR58,4), which inhibited chemokine-induced migration in vitro with an ED$_{50}$ of 5nM. However, further studies revealed that the aminoglutarimide ring was susceptible to enzymatic ring opening in serum. Consequently, for some applications (for example, where the inflammation under treatment is chronic, such as in autoimmune diseases) these compounds may not have optimal properties, and a more stable compound with similar anti-inflammatory properties may be superior.

As an approach to identifying such stable anlogs, various derivatives of (S)-3-(undec-10-enoyl)-aminoglutarimide have been tested for their stability in serum. One such derivative, the 6-deoxo analog (S)-3-(undec-10-enoyl)-tetrahydropyridin-2-one, is completely stable in human serum for at least 7 days at 37°C, but has considerably reduced potency compared with the parental molecule.
Amide derivatives of 3-aminocaprolactam have already been disclosed in the art. For example:

Japanese patent application No. 09087331 describes 3-aminocaprolactam amide derivatives wherein the amide alkyl side chain may contain from 2 to 30 carbon atoms. These compounds have been presented as oil-gelling agents.

US patent No. 6,395,282 describes immunogenic conjugates comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria, wherein said autoinducer can be a 3-aminocaprolactam amide derivative wherein the amide alkyl side chain may contain up to 34 carbon atoms. However, a therapeutic use is disclosed only for the conjugates and not for the isolated amide derivative.

An article by Weiss et al. (Research Communications in Psychology, Psychiatry and Behavior (1992), 17(3-4), 153-159) discloses a series of 3-aminocaprolactam amide derivatives, and among others 3-hexanamido-DL-\(\varepsilon\)-caprolactam and 3-dodecanamido-DL-\(\varepsilon\)-caprolactam. These compounds are presented as having only an in vitro activity but no significant in vivo effect.

In other words, though some alkyl amide derivatives of 3-aminocaprolactam have certainly been known in the art, no actual pharmaceutical use has been described for 3-aminocaprolactam amide derivatives.

The invention provides the use of a compound of general formula (I), or a pharmaceutically acceptable salt thereof, for the preparation of a medicament intended to treat inflammatory disorder:

\[
\text{R}^1 \quad \text{R}^2 \\
\begin{array}{c}
\text{N} \\
\text{O} \\
\text{NH}
\end{array}
\]

(I)

wherein

\(X = -\text{CO}-Y-(\text{R}^1)_{\text{n}} \) or \(\text{SO}_2-Y-(\text{R}^1)_{\text{n}}\),
Y is a cycloalkyl or polycycloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group);

or is a cycloalkenyl or polycycloalkenyl group;

each R¹ is independently selected from hydrogen or an alkyl, haloalkyl, alkoxy, haloalkoxy, alkynyl, alkylamino radical of 1 to 20 carbon atoms (for example of 5 to 20 carbon atoms, of 8 to 20 carbon atoms, of 9 to 20 carbon atoms, of 10 to 18 carbon atoms, of 12 to 18 carbon atoms, of 13 to 18 carbon atoms, of 14 to 18 carbon atoms, of 13 to 17 carbon atoms);

or each R¹ is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radical; and

n is any integer from 1 to m, where m is the maximum number of substitutions permissible on the cyclo-group Y.

Alternatively R¹ may be selected from a peptido radical, for example having from 1 to 4 peptidic moieties linked together by peptide bonds (for example a peptido radical of 1 to 4 amino acid residues).

The carbon atom at position 3 of the caprolactam ring is asymmetric and consequently, the compounds according to the present invention have two possible enantiomeric forms, that is, the “R” and “S” configurations. The present invention encompasses the two enantiomeric forms and all combinations of these forms, including the racemic “RS” mixtures. With a view to simplicity, when no specific configuration is shown in the structural formulae, it should be understood that the two enantiomeric forms and their mixtures are represented.

Preferably, the compounds of general formula (I) or pharmaceutically acceptable salts thereof used according to this aspect of the invention will be compounds of general formula (I')

(I')

F:\Client Docs\SCRAS\47746\SPEC\47746.W001.Spec.doc
wherein X has the same meaning as above.

Preferably, the compounds of general formula (I) or (I'), or their pharmaceutically acceptable salts, will be such that the ring or rings of Y constrain the bond angles at the alpha-carbon to be essentially tetrahedral (i.e. sp3 hybrid bonds). The “alpha carbon” is either at the 2-position (relative to the amide carbonyl) or at the 1-position (relative to the sulfonamide sulfonyl group).

Any substituent $R^1$ may be a substituent at any permissible position on the ring or rings of the cyclo-group Y. In particular it is to be noted that the invention includes compounds in which the “alpha carbon” is both part of the cyclo group and is itself substituted. The definition of ($R^1$)$_n$ encompasses compounds of the invention with no substitution (i.e. $R^1$ = hydrogen), compounds of the invention with mono substitution (i.e. $R^1$ is not hydrogen and $n = 1$), and also multiple substitution (i.e. at least two $R^1$ groups are not hydrogen and $n = 2$ or more).

The invention also provides pharmaceutical compositions comprising, as active ingredient, a compound of general formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient and/or carrier:

![Diagram](image)

(I)

wherein

$X$ is $-CO-Y-(R^1)_n$ or $SO_2-Y-(R^1)_n$;

$Y$ is a cycloalkyl or polycycloalkyl group (such as an adamantyl, adamantanimethyl, bicyclooctyl, cyclohexyl, cyclopropyl group);

or is a cycloalkenyl or polycycloalkenyl group;

each $R^1$ is independently selected from hydrogen or an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radical of 1 to 20 carbon atoms (for example of 5 to 20 carbon atoms, of 8 to 20 carbon atoms, of 9 to 20 carbon atoms, of 10 to 18
carbon atoms, of 12 to 18 carbon atoms, of 13 to 18 carbon atoms, of 14 to 18 carbon atoms, of 13 to 17 carbon atoms); 

or each $R^1$ is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radical; and 

$n$ is any integer from 1 to $m$, where $m$ is the maximum number of substitutions permissible on the cyclo-group $Y$.

Alternatively $R^1$ may be selected from a peptido radical, for example having from 1 to 4 peptidic moieties linked together by peptide bonds (for example a peptido radical of 1 to 4 amino acid residues).

Preferably, the compounds of general formula (I) or pharmaceutically acceptable salts thereof used according to this aspect of the invention will be compounds of general formula (I')

![Chemical Structure](image)

(I')

wherein $X$ has the same meaning as above.

By pharmaceutically acceptable salt is meant in particular the addition salts of inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate, diphosphate and nitrate or of organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulphonate, p-toluencesulphonate, palmoate and stearate.

Also within the scope of the present invention, when they can be used, are the salts formed from bases such as sodium or potassium hydroxide. For other examples of pharmaceutically acceptable salts, reference can be made to "Salt selection for basic drugs", *Int. J. Pharm.* (1986), **33**, 201-217.

The pharmaceutical composition can be in the form of a solid, for example powders, granules, tablets, gelatin capsules, liposomes or suppositories. Appropriate solid supports can be, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose,
polyvinylpyrrolidone and wax. Other appropriate pharmaceutically acceptable excipients and/or carriers will be known to those skilled in the art.

The pharmaceutical compositions according to the invention can also be presented in liquid form, for example, solutions, emulsions, suspensions or syrups. Appropriate liquid supports can be, for example, water, organic solvents such as glycerol or glycols, as well as their mixtures, in varying proportions, in water.

The invention also provides compounds and salts thereof of general formula (I)

\[ \text{(I)} \]

wherein

X is \(-CO-Y-(\text{R}^1)_n\) or \(\text{SO}_2-Y-(\text{R}^1)_2\);

Y is a cycloalkyl or polycycloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group);

or is a cycloalkenyl or polycycloalkenyl group;

each \(\text{R}^1\) is independently selected from hydrogen or an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radical of 1 to 20 carbon atoms (for example of 5 to 20 carbon atoms, of 8 to 20 carbon atoms, of 9 to 20 carbon atoms, of 10 to 18 carbon atoms, of 12 to 18 carbon atoms, of 13 to 18 carbon atoms, of 14 to 18 carbon atoms, of 13 to 17 carbon atoms);

or each \(\text{R}^1\) is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radical; and

n is any integer from 1 to m, where m is the maximum number of substitutions permissible on the cyclo-group Y.
Alternatively R\textsuperscript{1} may be selected from a peptido radical, for example having from 1 to 4 peptidic moieties linked together by peptide bonds (for example a peptido radical of 1 to 4 amino acid residues).

Preferably, the compounds of general formula (I) or salts thereof used according to this aspect of the invention will be compounds of general formula (I')

![Chemical structure](image)

(I')

wherein X has the same meaning as above.

Preferably, the compounds of general formula (I) or (I') when used in the invention, or their salts, will be such that the ring or rings of Y constrain the bond angles at the alpha-carbon to be essentially tetrahedral (i.e. sp\textsuperscript{3} hybrid bonds).

In particular, preferred compounds of general formula (I) or (I') and their salts according to any aspect of the present invention are selected from the group consisting of:

- (S)-3-[(Cyclohexanecarbonyl)amino-caprolactam;
- (S)-3-[(1'-methylcyclohexanecarbonyl)amino-caprolactam;
- (S)-3-[(Cyclohex-1’-ene-carbonyl)amino-caprolactam;
- (S)-3-[(trans-4’-pentylecyclohexane-1-carbonyl)amino-caprolactam;
- (S)-3-[(4’-pentyl[2,2,2]bicyclo-octane-1-carbonyl)amino-caprolactam;
- (S)-3-[(1’-Adamantane-carbonyl)amino-caprolactam;
- (S)-3-[(1’-Adamantanyl-methanecarbonyl)amino-caprolactam;
- (S)-3-[(3’-chloro-1’-adamantane-carbonyl)amino-caprolactam;
- (S)-3-[(3’,5’-Dimethyl-1’-adamantane-carbonyl)amino-caprolactam;
- (S)-3-(3',5',7'-Trimethyl-1'- adamantanecarbonyl)amino-caprolactam;

and the salts thereof.

The most preferred compound is (S)-3-(1'-Adamantanecarbonyl)amino-caprolactam and salts thereof.

The invention also provides the sulfonamide analogues of the exemplified compounds: i.e. the sulfonyl-amino-caprolactam equivalents of the said compounds.

As mentioned in the discussion of prior art above, certain alkyl amide derivatives of 3-amino caprolactam may be known as compounds per se (though it is not presently known that any have been described as such as pharmaceutical compositions or for medical use in an anti-inflammatory context).

The invention includes compounds, compositions and uses thereof as defined, wherein the compound is in hydrated or solvated form.

The amide derivatives of 3-aminocaprolactam described here are functional BSCIs. They are relatively inexpensive to synthesise, using facile synthesis routes provided herein; they are stable in human serum and consequently have excellent pharmacokinetic properties; they are orally bioavailable; they are highly potent broad-spectrum chemokine inhibitors in vitro with excellent selectivity over non-chemokine chemoattractants; they are highly potent and effective anti-inflammatory agents in vivo in rodent models of inflammation; their administration is not associated with any significant acute toxicity at the doses necessary to achieve a maximal therapeutic effect. Taken together, these properties suggest that amide derivatives of 3-aminocaprolactam represent anti-inflammatory medications with advantages over previously described compounds.

In comparison to the prior art the improvement of the present invention lies in the provision of the 3-aminocaprolactam moiety with a side chain having one or more alkyl/alkenyl rings to constrain the bond angles at the alpha carbon of the side chain. Compounds of this invention are significantly superior to compounds with linear allyl chains (whether alkyl amides or alkyl sulfonamides).

Prior art peptides (such as NR.58-3.14.3) have the disadvantages that: (a) they are expensive and require solid phase synthesis (at least for the longer ones) and (b) they clear very quickly via the kidneys and (c) they are generally less potent.
The prior art aminoglutarimides are cheap, not cleared quickly via the kidneys and more potent BUT they do not show metabolic stability.

The improvement described here, the aminocaprolactams, are cheap, not cleared by the kidney and even more potent, and are also metabolically stable.

According to this invention, inflammatory disorders intended to be prevented or treated by the compounds of general formula (I) or (II) or the pharmaceutically acceptable salts thereof or pharmaceutical compositions or medicaments containing them as active ingredients include notably:

- autoimmune diseases, for example such as multiple sclerosis;
- vascular disorders including stroke, coronary artery diseases, myocardial infarction, unstable angina pectoris, atherosclerosis or vasculitis, e. g., Behçet's syndrome, giant cell arteritis, polymyalgia rheumatica, Wegener's granulomatosis, Churg-Strauss syndrome vasculitis, Henoch-Schönlein purpura and Kawasaki disease;
- viral infection or replication, e.g. infections due to or replication of viruses including pox virus, herpes virus (e. g., Herpesvirus samiri), cytomegalovirus (CMV) or lentivirus;
- asthma;
- osteoporosis; (low bone mineral density);
- tumor growth;
- rheumatoid arthritis;
- organ transplant rejection and/or delayed graft or organ function, e.g. in renal transplant patients;
- a disorder characterised by an elevated TNF-α level;
- psoriasis;
- skin wounds;
- disorders caused by intracellular parasites such as malaria or tuberculosis;
- allergies; or
- Alzheimer’s disease.

According to this invention, further inflammatory disorders include:

- ALS;
- fibrosis (particularly pulmonary fibrosis, but not limited to fibrosis in the lung);
- the formation of adhesions (particularly in the peritoneum and pelvic region).
- antigen induced recall response
- immune response suppression

These clinical indications fall under the general definition of inflammatory disorders or disorders characterized by elevated TNFα levels.

Where legally permissible, the invention also provides a method of treatment, amelioration or prophylaxis of the symptoms of an inflammatory disease (including an adverse inflammatory reaction to any agent) by the administration to a patient of an anti-inflammatory amount of a compound, composition or medicament as claimed herein.

Administration of a medicament according to the invention can be carried out by topical, oral, parenteral route, by intramuscular injection, etc.

The administration dose envisaged for a medicament according to the invention is comprised between 0.1 mg and 10 g depending on the type of active compound used.

According to the invention, the compounds of general formula (I) or (I') can be prepared using the processes described hereafter.

**Preparation of the compounds of general formula (I) or (I')**

All the compounds of general formula (I') or (I') can be prepared easily according to general methods known to the person skilled in the art.

Nevertheless, the following preferred synthetic route is proposed:
Diagram 1

The reaction shown in Diagram 1 may be carried out, for example, in chloroform or dichloromethane. The most preferred reaction solvent is dichloromethane.

The above reaction is preferably carried out in the presence of a base, for example Na₂CO₃.

The above reaction may be carried out at ambient temperature (about 25 °C) or more generally at a temperature between 20 and 50 °C.

DEFINITIONS

The term “about” refers to an interval around the considered value. As used in this patent application, “about X” means an interval from X minus 10% of X to X plus 10% of X, and preferably an interval from X minus 5% of X to X plus 5% of X.

The use of a numerical range in this description is intended unambiguously to include within the scope of the invention all individual integers within the range and all the combinations of upper and lower limit numbers within the broadest scope of the given range. Hence, for example, the range of 1 to 20 carbon atoms specified in respect of (inter alia) formula I is intended to include all integers between 4 and 20 and all subranges of each combination of upper and lower numbers, whether exemplified explicitly or not.

As used herein, the term “comprising” is to be read as meaning both comprising and consisting of. Consequently, where the invention relates to a “pharmaceutical composition comprising as active ingredient” a compound, this terminology is intended to cover both compositions in which other active ingredients may be present and also compositions which consist only of one active ingredient as defined.

The term “peptidic moieties” used herein is intended to include the following 20 naturally-occurring proteogenic amino acid residues:
<table>
<thead>
<tr>
<th>SYMBOL</th>
<th>MEANING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ala</td>
<td>Alanine</td>
</tr>
<tr>
<td>Cys</td>
<td>Cysteine</td>
</tr>
<tr>
<td>Asp</td>
<td>Aspartic Acid</td>
</tr>
<tr>
<td>Glu</td>
<td>Glutamic Acid</td>
</tr>
<tr>
<td>Phe</td>
<td>Phenylalanine</td>
</tr>
<tr>
<td>Gly</td>
<td>Glycine</td>
</tr>
<tr>
<td>His</td>
<td>Histidine</td>
</tr>
<tr>
<td>Ile</td>
<td>Isoleucine</td>
</tr>
<tr>
<td>Lys</td>
<td>Lysine</td>
</tr>
<tr>
<td>Leu</td>
<td>Leucine</td>
</tr>
<tr>
<td>Met</td>
<td>Methionine</td>
</tr>
<tr>
<td>Asn</td>
<td>Asparagine</td>
</tr>
<tr>
<td>Pro</td>
<td>Proline</td>
</tr>
<tr>
<td>Gln</td>
<td>Glutamine</td>
</tr>
<tr>
<td>Arg</td>
<td>Arginine</td>
</tr>
<tr>
<td>Ser</td>
<td>Serine</td>
</tr>
<tr>
<td>Thr</td>
<td>Threonine</td>
</tr>
<tr>
<td>Val</td>
<td>Valine</td>
</tr>
<tr>
<td>Trp</td>
<td>Tryptophan</td>
</tr>
<tr>
<td>Tyr</td>
<td>Tyrosine</td>
</tr>
</tbody>
</table>

Modified and unusual amino acid residues, as well as peptido-mimetics, are also intended to be encompassed within the definition of "peptidic moieties".

Unless otherwise defined, all the technical and scientific terms used here have the same meaning as that usually understood by an ordinary specialist in the field to which this invention belongs. Similarly, all the publications, patent applications, all the patents and all other references mentioned here are incorporated by way of reference (where legally permissible).
The following examples are presented in order to illustrate the above procedures and should in no way be considered to limit the scope of the invention.

FIGURES

Figure 1 shows the chemical structure of examples of compounds according to the invention.

EXAMPLES

General procedure for the synthesis of the starting compounds

The hydrochlorides of (R) and (S)-3-amino-caprolactam, and the hydro-pyrrolidine-5-carboxylates of (R,R) and (S,S)-3-amino-caprolactam were synthesised according to literature (cf. Boyle et al., J. Org. Chem., (1979), 44, 4841-4847; Rezler et al., J. Med. Chem. (1997), 40, 3508-3515).

Example 1: (S)-3-(Cyclohexanecarbonyl)amino-caprolactam:

(S,S)-3-amino-caprolactam hydro-pyrrolidine-5-carboxylate 2 (5 mmol) and Na₂CO₃ (15 mmol) in water (25 ml) were added to a solution of cyclohexanecarbonyl chloride (5 mmol) in dichloromethane (25 ml) at ambient temperature and the reaction was stirred for 12 hours. The organic layer was then separated and the aqueous phase was extracted with additional dichloromethane (2 × 25 ml). The combined organic layers were dried over Na₂CO₃ and reduced in vacuo. The residue was purified by recrystallisation from EtOAc / hexane to give the lactam (540 mg, 45%); m.p. (EtOAc / hexanes) 180-181 °C; [α]°D (c = 1, CHCl₃) +42.0; ν_max/cm⁻¹ 3294 (NH), 1668, 1614 (CO), 1537 (NH); δ_H (500 MHz, CDCl₃) 6.89 (1H, d, J 5.5, CHNH); 6.51 (1H, br s, CH₂NH), 4.48 (1H, dd, J 11, 6, CHNH), 3.30-3.17 (2H, m, CH₂NH), 2.11 (1H, tt, J 11.5, 3.5, (CH₃)CHCO), 2.01 (1H, br d, J 13, lactam ring CH), 1.98-1.92 (1H, m, lactam ring CH), 1.87-1.70 (6H, m, lactam ring CH ×2 + cyhex CH ×4), 1.66-1.59 (1H, m, cyhex CH), 1.47-1.30 (4H, br m, lactam ring CH ×2 + cyhex CH ×2) and 1.23-1.15 (3H, m, cyhex CH ×3); δ_C (125 MHz, CDCl₃) 175.9, 175.3 (CO), 51.8 (NHCHCO), 45.2 (CH), 42.1, 31.7, 29.6, 29.4, 28.9, 27.9, 25.7 (×2), 25.6 (CH₂); m/z (M⁺ C₁₃H₂₉N₂O₂ requires 238.16813) 238.16768.

Example 2: (S)-3-(1'-methylcyclohexanecarbonyl)amino-caprolactam:

(S,S)-3-amino-caprolactam hydro-pyrrolidine-5-carboxylate 2 (5 mmol) and Na₂CO₃ (15 mmol) in water (25 ml) were added to a solution of 1-methylcyclohexanecarbonyl chloride (5 mmol) in dichloromethane (25 ml) at ambient temperature and the reaction was stirred for 12 hours. The organic layer was then separated and the aqueous phase was
extracted with additional dichloromethane (2 × 25 ml). The combined organic layers were dried over Na₂CO₃ and reduced in vacuo. The residue was purified by recrystallisation from EtOAc / hexanes give the lactam (540 mg, 43%); m.p. (EtOAc / hexanes) 168-169 °C; [α]D²⁰ (c = 1, CHCl₃) +33.0; νmax/cm⁻¹ 3380, 3241 (NH), 1674, 1638 (CO), 1501 (NH); δH (500 MHz, CDCl₃) 7.12 (1H, d, J 5, CHNH), 6.52 (1H, br s, CH₂NH), 4.48 (1H, ddd, J 11, 5.5, 1.5 CHNH), 3.30-3.16 (2H, m, CH₂NH), 2.01 (1H, br d, J 13, lactam ring CH), 1.98-1.86 (3H, m, lactam ring CH + cyhex CH ×2), 1.85-1.73 (2H, m, lactam ring CH ×2), 1.56-1.47 (2H, m, cyhex CH ×2), 1.47-1.33 (5H, br m, lactam ring CH ×2 + cyhex CH ×3) and 1.33-1.25 (3H, m, cyhex CH ×3); δC (125 MHz, CDCl₃) 176.9, 167.0 (CO), 52.0 (NHCHCO), 42.5 (Cquat), 42.1, 35.5 (×2), 31.6, 28.9, 27.9 (CH₂), 26.4 (CH₃), 25.8, 22.9 (×2) (CH₂); m/z (M⁺ C₁₄H₂₄N₂O₂ requires 252.18378) 252.18323.

Example 3: (S)-3-(Cyclohex-1'-enecarbonyl)amino-caprolactam:
(S,S)-3-amino-caprolactam hydro-pyrrolidine-5-carboxylate 2 (5 mmol) and Na₂CO₃ (15 mmol) in water (25 ml) were added to a solution of cyclohex-1-ene-1-carbonyl chloride (5 mmol) in dichloromethane (25 ml) at ambient temperature and the reaction was stirred for 12 hours. The organic layer was then separated and the aqueous phase was extracted with additional dichloromethane (2 × 25 ml). The combined organic layers were dried over Na₂CO₃ and reduced in vacuo. The residue was purified by recrystallisation from EtOAc / hexanes give the lactam (431 mg, 36%); m.p. (EtOAc / hexanes) 151-152 °C; [α]D²⁰ (c = 1, CHCl₃) +57.5; νmax/cm⁻¹ 3219 (NH), 1652, 1628 (C=O, C=C), 1515 (NH); δH (500 MHz, CDCl₃) 7.12 (1H, d, J 5, CHNH), 6.67 (1H, qn, J 1.5, CH=C), 6.52 (1H, br s, CH₂NH), 4.54 (1H, ddd, J 11, 5.5, 1.5 CHNH), 3.32-3.18 (2H, m, CH₂NH), 2.30-2.17 (2H, m, CH₂CH=C), 2.16-2.10 (2H, m, CH=CCH₂), 2.07 (1H, br d, J 15, lactam ring CH), 2.00-1.92 (1H, m, lactam ring CH), 1.87-1.76 (2H, m, lactam ring CH ×2), 1.68-1.60 (2H, m, cyhex CH ×2), 1.60-1.52 (2H, m, cyhex CH ×2) and 1.50-1.31 (2H, br m, lactam ring CH ×2); δC (125 MHz, CDCl₃) 175.9, 167.4 (CO), 134.0 (CH=C), 132.8 (CH=C), 52.1 (NHCHCO), 42.1, 31.6, 28.9, 27.9, 25.3, 24.0, 22.1, 21.5 (CH₂); m/z (M⁺ C₁₃H₂₀N₂O₂ requires 236.15248) 236.15208.

Example 4: (S)-3-(trans-4'-pentylocyclohexane-1-carbonyl)amino-caprolactam:
(S,S)-3-amino-caprolactam hydro-pyrrolidine-5-carboxylate 2 (7 mmol) and Na₂CO₃ (21 mmol) in water (25 ml) were added to a solution of trans-4-pentylocyclohexane-1-carbonyl chloride (6 mmol) in dichloromethane (25 ml) at ambient temperature and the reaction was stirred for 12 hours. The organic layer was then separated and the aqueous phase was extracted with additional dichloromethane (2 × 25 ml). The combined organic layers were dried over Na₂CO₃ and reduced in vacuo. The residue was purified by
recrystallisation from EtOAc / hexane to give the lactam (977 mg, 53%); m.p. 182-184 °C; [α]_D^20 (c = 1, CHCl₃) +32.2; νmax/cm⁻¹ 3326 (NH), 1670, 1636 (CO), 1511 (NH); δH (500 MHz, CDCl₃) 6.91 (1H, d, J 5.5, CHNH), 6.87-6.70 (1H, br m, CH₂NH), 4.44 (1H, ddd, J 11, 6.0, 1.5, CH₂NH), 3.28-3.15 (2H, m, CH₂NH), 2.08-1.90 (3H, br m, ring CH ×2 + CH₂CO), 1.88-1.72 (6H, m, ring CH + chain CH₂ × 4), 1.45-1.28 (4H, br m, ring CH + chain CH₃ × 2 + chain CH(CH₃)₂), 1.27-1.07 (9H, br m, ring CH + chain CH₃ × 8) and 0.90-0.79 (5H, m, chain CH₂ + CH₃); δC (125 MHz, CDCl₃) 176.0, 175.3 (CO), 51.8 (NHCHCO), 45.4 (CH), 41.0 (CH₂), 37.1 (CH₃), 36.9 (CH), 32.5, 32.4, 32.1, 31.7, 29.6, 29.4, 28.9, 27.9, 26.5, 22.6 (CH₂) and 14.0 (CH₃); m/z (M⁺ C₁₈H₃₂N₂O₂ requires 308.24638) 308.24566.

**Example 5:** (S)-3-(4'-pentyl[2,2,2]bicyclo-octane-1-carbonyl)amino-caprolactam:

(S,S)-3-amino-caprolactam hydro-pyrrolidine-5-carboxylate 2 (5.5 mmol) and Na₂CO₃ (16.5 mmol) in water (25 ml) were added to a solution of trans-4-pentylcyclohexane-1-carbonyl chloride (4.4 mmol) in dichloromethane (25 ml) at ambient temperature and the reaction was stirred for 12 hours. The organic layer was then separated and the aqueous phase was extracted with additional dichloromethane (2 × 25 ml). The combined organic layers were dried over Na₂CO₃ and reduced in vacuo. The residue was purified by recrystallisation from EtOAc / hexane to give the lactam (868 mg, 57%); m.p. 195-196 °C; [α]_D^20 (c = 1, CHCl₃) +28.7; νmax/cm⁻¹ 3395, 3254 (NH), 1677, 1626 (CO), 1501 (NH); δH (500 MHz, CDCl₃) 6.98 (1H, d, J 5.5, CHNH), 6.77-6.63 (1H, br m, CH₂NH), 4.41 (1H, dd, J 11, 5.5, CHNH), 3.27-3.15 (2H, m, CH₂NH), 2.00-1.88 (2H, br m, ring CH ×2), 1.81-1.73 (2H, br m, ring CH ×2), 1.69 (6H, br t, J 7.5, chain CCH₂CH₂C × 6), 1.43-1.30 (8H, br m, ring CH ×2 + chain CCH₂CH₂C × 6), 1.24 (2H, sext, J 7, CH₂CH₃), 1.19-1.07 (4H, m, CH₂CH₂CH₂CH₃) 1.05-0.98 (2H, m, CH₂Bu) and 0.82 (3H, t, J 7, CH₃); δC (125 MHz, CDCl₃) 177.4, 176.1 (CO), 51.9 (NHCHCO), 42.0, 41.2 (CH₂), 39.0 (C quat), 32.7, 31.6, 30.6 (×3) (CH₃), 30.4 (C quat), 28.9, 28.8 (×3), 27.9, 23.3, 22.6 (CH₂) and 14.0 (CH₃); m/z (M⁺ C₂₀H₃₄N₂O₂ requires 334.26203) 334.26352.

**Example 6:** (S)-3-(1'-Adamantane-carbonyl)amino-caprolactam:

(S)-3-amino-caprolactam hydrochloride 2 (1 mmol) and Na₂CO₃ (3 mmol) in water (15 ml) were added to a solution of 1-adamantane-carbonyl chloride (1 mmol) in dichloromethane (15 ml) at ambient temperature and the reaction was stirred for 2 hours. The organic layer was then separated and the aqueous phase was extracted with additional dichloromethane (2 × 25 ml). The combined organic layers were dried over Na₂CO₃ and reduced in vacuo. The residue was recrystallised from CH₂Cl₂ / hexanes to give (S)-3-(1'-adamantane-carbonyl)amino-caprolactam (171 mg, 59%); m.p. 256-258 °C; [α]_D^20 (c = 1,
Example 7: (S)-3-(1'-Adamantanylmethylene carbonyl)amino-caprolactam:

(S)-3-amino-caprolactam hydrochloride 2 (4 mmol) and Na₂CO₃ (12 mmol) in water (50 ml) were added to a solution of 1-adamantanemethanecarbonyl chloride (4 mmol) in dichloromethane (50 ml) at ambient temperature and the reaction was stirred for 2 hours. The organic layer was then separated and the aqueous phase was extracted with additional dichloromethane (2 x 50 ml). The combined organic layers were dried over Na₂SO₄ and reduced in vacuo. The residue was recrystallised from EtOAc / hexane to give (S)-3-(1'-adamantanylmethylene carbonyl)amino-caprolactam, recrystallised from EtOAc to give white crystals (688 mg, 56%); m.p. 258-260 °C; [α]₅³ (c = 1, CHCl₃) +30.7; νmax/cm⁻¹ 3409, 3255 (NH), 1682, 1611 (CO), 1539 (NH); δH (500 MHz, CDCl₃) 6.82 (1H, d, J 5.5, CHNH), 6.77 (1H, br t, J 5.5, CH₂NH), 4.48 (1H, ddd, J 11, 6, 1.5, CH₂NH), 3.28-3.14 (2H, m, CH₂NH), 2.04 (1H, br d, J 13.5, C-4 H), 1.97-1.86 (6H, m, C-5 H + 3 × adamantane CH + CH₂CO), 1.84-1.72 (2H, m, C-5 H + C-6 H), 1.63 (3H, br d, J 12, adamantane 3 × CH₂), 1.60-1.54 (9H, m, 9 × adamantane CH₂) and 1.47-1.27 (2H, m, C-4 H + C-6 H); δC (125 MHz, CDCl₃) 175.9 (lactam CO), 170.1 (amide CO), 52.0 (NHCO), 42.6 (3 × adamantane CH₂), 42.0 (NCH₂), 36.7 (3 × CH₂ adamantane), 32.7 (Cquat adamantane), 31.7 (C-4), 28.8 (C-6), 28.6 (3 × CH adamantane), 28.5 (C-5); m/z (M⁺ C₁₇H₂₇N₂O₄ requires 304.2151) 304.21430.

Example 8: (S)-3-(3'-chloro-1'-adamantanecarbonyl)amino-caprolactam:

(S)-3-amino-caprolactam hydrochloride 2 (3 mmol) and Na₂CO₃ (9 mmol) in water (15 ml) were added to a solution of 3-chloro-1-adamantanecarbonyl chloride (3 mmol) in dichloromethane (15 ml) at ambient temperature and the reaction was stirred for 12 hours. The organic layer was then separated and the aqueous phase was extracted with additional dichloromethane (2 x 25 ml). The combined organic layers were dried over Na₂CO₃ and reduced in vacuo. The residue was recrystallised from EtOAc / Hexane to give (S)-3-(3'-chloro-1'-adamantanecarbonyl)amino-caprolactam (621 mg, 64%); m.p. 204-206 °C; [α]₅³
Example 9: (S)-3-(3',5',7'-Dimethyl-1'-adamantanecarbonyl)amino-capro lactam: (S)-3-amino-caprolactam hydrochloride 2 (1 mmol) and Na₂CO₃ (3 mmol) in water (15 ml) were added to a solution of 3,5-dimethyl-1-adamantanecarbonyl chloride (1 mmol) in dichloromethane (15 ml) at ambient temperature and the reaction was stirred for 12 hours. The organic layer was then separated and the aqueous phase was extracted with additional dichloromethane (2 × 25 ml). The combined organic layers were dried over Na₂CO₃ and reduced in vacuo. The residue was recrystallised from hexane to give (S)-3-(3',5'-dimethyl-1'-adamantanecarbonyl)amino-capro lactam (200 mg, 63%); m.p. 157-158 °C; [α]D²⁰ (c = 0.5, CHCl₃) +26.8; νmax/cm⁻¹ 3206 (NH), 1647 (CO), 1548 (NH); δH (500 MHz, CDCl₃) 7.05 (1H, d, J 5.0, CHNH), 6.49-6.24 (1H, br m, CH₂NH), 4.45 (1H, ddd, J 11, 5.5, 1.5, CHNH), 3.30-3.16 (2H, m, CH₂NH), 2.12-2.07 (1H, m, adamantane CH), 2.04-1.90 (2H, m, 2 × lactam ring CH), 1.86-1.73 (2H, m, 2 × lactam ring CH), 1.67 (2H, br s, 2 × adamantane CH), 1.51-1.26 (10H, br m, 8 × adamantane CH + 2 × lactam ring CH) 1.17-1.09 (2H, m, adamantane CH) and 0.81 (6H, s, 2 × CH₃); δC (125 MHz, CDCl₃) 176.9, 176.0 (CO), 51.9 (NHCHCO), 50.6, 45.2 (×2), 42.7 (×2) (CH₂ adamantane), 42.4 (CCO), 42.1 (CH₂N), 37.7 (CH₃ adamantane), 31.6 (CH₂ lactam), 31.0 (2 × CH₃), 30.4, 29.3 (CH₃), 28.9 and 27.9 (CH₂ lactam); m/z (MH⁺ C₁₉H₂₇N₂O₂Cl requires 319.2386) 319.2372.

Example 10: (S)-3-(3',5',7'-Trimethyl-1'-adamantanecarbonyl)amino-caprolactam: (S)-3-amino-caprolactam hydrochloride 2 (1 mmol) and Na₂CO₃ (3 mmol) in water (15 ml) were added to a solution of 3,5,7-trimethyl-1-adamantanecarbonyl chloride (1 mmol) in dichloromethane (15 ml) at ambient temperature and the reaction was stirred for 12 hours. The organic layer was then separated and the aqueous phase was extracted with additional dichloromethane (2 × 25 ml). The combined organic layers were dried over Na₂CO₃ and reduced in vacuo. The residue was recrystallised from EtOAc / hexane to
give (S)-3-(3',5',7'-trimethyl-1'-adamantanecarbonyl)amino-caprolactam (188 mg, 56%); m.p. 177-178 °C; [α]D20 (c = 0.5, CHCl₃) +25.6; νmax/cm−1 3377, 3220 (NH), 1677, 1623 (CO), 1514 (NH); δH (500 MHz, CDCl₃) 7.06 (1H, d, J 5.0, CHNH), 6.40-6.15 (1H, br m, CH₂NH), 4.46 (1H, ddd, J 11, 5.5, 1.5, CH/CH₃), 3.32-3.17 (2H, m, CH₂NH), 2.03-1.92 (2H, m, 2 × lactam ring CH), 1.86-1.74 (2H, m, 2 × lactam ring CH) 1.47-1.32 (8H, m, 2 × ring CH + 6 × adamantane CH) 1.06 (3H, br d, J 12, 3 × adamantane CH/CH₃), 1.04 (3H, br d, J 12, 3 × adamantane CH/CH₃) and 0.83 (9H, s, 3 × CH₃); δc (125 MHz, CDCl₃) 176.8, 176.0 (CO), 51.9 (NHCHCO), 50.0 (3 × CH₂ adamantane), 44.6 (3 × CH₂ adamantane), 43.4 (CCO), 42.1 (CH₂N), 31.8 (3 × CH₂), 31.7 (CH₂ lactam), 30.0 (3 × CH₃), 28.9, 27.9 (CH₂ lactam); m/z (MH⁺ C₂₀H₃₅N₂O₂ requires 333.2542) 333.2528.

**Pharmacological study of the products of the invention**

**Inhibition of MCP-1 induced leukocyte migration**

**Assay principle**

The biological activity of the compounds of the current invention may be demonstrated using any of a broad range of functional assays of leukocyte migration in vitro, including but not limited to Boyden chamber and related transwell migration assays, under-agarose migration assays and direct visualisation chambers such as the Dunn Chamber.

For example, to demonstrate the inhibition of leukocyte migration in response to chemokines (but not other chemoattractants) the 96-well format micro transwell assay system from Neuroprobe (Gaithersburg, MD, USA) has been used. In principle, this assay consists of two chambers separated by a porous membrane. The chemoattractant is placed in the lower compartment and the cells are placed in the upper compartment.

After incubation for a period at 37°C the cells move towards the chemoattractant, and the number of cells in the lower compartment is proportional to the chemoattractant activity (relative to a series of controls).

This assay can be used with a range of different leukocyte populations. For example, freshly prepared human peripheral blood leukocytes may used. Alternatively, leukocyte subsets may be prepared, including polymorphonuclear cells or lymphocytes or monocytes using methods well known to those skilled in the art such as density gradient centrifugation or magnetic bead separations. Alternatively, immortal cell lines which have been extensively validated as models of human peripheral blood leukocytes may be
used, including, but not limited to THP-1 cells as a model of monocytes or Jurkat cells as model of naïve T cells.

Although a range of conditions for the assay are acceptable to demonstrate the inhibition of chemokine-induced leukocyte migration, a specific example is hereby provided.

**Materials**

The transwell migration systems are manufactured by Neuroprobe, Gaithersburg, MD, USA.

The plates used are ChemoTx plates (Neuroprobe 101-8) and 30 μl clear plates (Neuroprobe MP30).

Geys’ Balanced Salt Solution is purchased from Sigma (Sigma G-9779).

Fatty acid-free BSA is purchased from Sigma (Sigma A-8806).

MTT, i.e. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, is purchased from Sigma (Sigma M-5655).

RPMI-1640 without phenol red is purchased from Sigma (Sigma R-8755).

The THP-1 cell line (European Cell culture Collection) were used as the leukocyte cell population.

**Test protocol**

The following procedure is used for testing the invention compounds for MCP-1 induced leukocyte migration:

First, the cell suspension to be placed in the upper compartment is prepared. The THP-1 cells are pelleted by centrifugation (770 x g; 4 mins) and washed with Geys Balanced Salt Solution with 1mg/ml BSA (GBSS + BSA). This wash is then repeated, and the cells repelleted before being resuspended in a small volume of GBSS + BSA for counting, for example using a standard haemocytometer.

The volume of GBSS + BSA is then adjusted depending on the number of cells present so that the cells are at final density of $4.45 \times 10^6$ cells per ml of GBSS + BSA. This ensures that there are 100,000 THP-1 cells in each 25μl of the solution that will be placed in the upper chamber of the plate.
To test a single compound for its ability to inhibit MCP-1 induced migration, it is necessary to prepare two lots of cells. The suspension of THP-1 cells at 4.45 x 10^6 cells/ml is divided into two pots. To one pot the inhibitor under test is added at an appropriate final concentration, in an appropriate vehicle (for example at 1 μM in not more than 1% DMSO). To the second pot an equal volume of GBSS + BSA plus vehicle as appropriate (e.g. not more than 1% DMSO) is added to act as a control.

Next, the chemoattractant solution to be placed in the lower compartment is prepared. MCP-1 is diluted in GBSS + BSA to give a final concentration of 25 ng/ml. This is divided into two pots, as for the cell suspension. To one pot, the test compound is added to the same final concentration as was added to the cell suspension, while to the other pot an equal volume of GBSS + BSA plus vehicle as appropriate (e.g. not more than 1% DMSO) is added.

Note that the volume of liquid that needs to be added to make the addition of the text compound needs to be taken into account, when establishing the final concentration of MCP-1 in the solution for the lower compartment and the final concentration of cells in the upper compartment.

Once the chemoattractant solutions for the lower wells and cell solutions for the upper chambers have been prepared, the migration chamber should be assembled. Place 29 μl of the appropriate chemoattractant solution into the lower well of the chamber. Assays should be performed with at least triplicate determinations of each condition. Once all the lower chambers have been filled, apply the porous membrane to the chamber in accordance with the manufacturer’s instructions. Finally, apply 25 μl of the appropriate cell solution to each upper chamber. A plastic lid is placed over the entire apparatus to prevent evaporation.

The assembled chamber is incubated at 37 °C, 5% CO₂, for 2 hours. A suspension of cells in GBSS + BSA is also incubated under identical conditions in a tube; these cells will be used to construct a standard curve for determining the number of cells that have migrated to the lower chamber under each condition.

At the end of the incubation, the liquid cell suspension is gently removed from the upper chamber, and 20μl of ice-cold 20mM EDTA in PBS is added to the upper chamber, and the apparatus is incubated at 4°C for 15 mins. This procedure causes any cells adhering to the underside of the membrane to fall into the lower chamber.
After this incubation the filter is carefully flushed with GBSS + BSA to wash off the EDTA, and then the filter is removed.

The number of cells migrated into the lower chamber under each condition can then be determined by a number of methods, including direct counting, labelling with fluorescent or radioactive markers or through the use of a vital dye. Typically, we utilise the vital dye MTT. 3 µl of stock MTT solution are added to each well, and then the plate is incubated at 37 °C for 1-2 hours during which time dehydrogenase enzymes within the cells convert the soluble MTT to an insoluble blue formazan product that can be quantified spectrophotometrically.

In parallel, an 8-point standard curve is set up. Starting with the number of cells added to each upper chamber (100,000) and going down in 2-fold serial dilutions in GBSS + BSA, the cells are added to a plate in 25 µl, with 3 µl of MTT stock solution added. The standard curve plate is incubated along side the migration plate.

At the end of this incubation, the liquid is carefully removed from the lower chambers, taking care not to disturb the precipitated formazan product. After allowing to air dry briefly, 20µl of DMSO is added to each lower chamber to solubilise the blue dye, and absorbance at 595nm is determined using a 96-well plate reader. The absorbance of each well is then interpolated to the standard curve to estimate the number of cells in each lower chamber.

The MCP-1 stimulated migration is determined by subtracting the average number of cells that reached the lower compartment in wells where no MCP-1 was added from the average number of cells that reached the lower compartment where MCP-1 was present at 25ng/ml.

The impact of the test substance is calculated by comparing the MCP-1-induced migration which occurred in the presence or absence of various concentrations of the test substance. Typically, the inhibition of migration is expressed as a percentage of the total MCP-1 induced migration which was blocked by the presence of the compound. For most compounds, a dose-response graph is constructed by determining the inhibition of MCP-1 induced migration which occurs at a range of different compound concentrations (typically ranging from 1nM to 1µM or higher in the case of poorly active compounds). The inhibitory activity of each compound is then expressed as the concentration of compound required to reduce the MCP-1-induced migration by 50% (the ED$_{50}$ concentration).
Results

The compounds of examples 1 to 8 and 10 were tested and were shown to have an ED$_{50}$ of 100 nM or less in this test.

Enantioselectivity

The (S)- and (R)- enantiomers of two different members of the aminocaprolactam series can be synthesised to determine whether the biological activity showed enantioselectivity.

The dose-response curves for each of the compounds as inhibitors of MCP-1 induced THP-1 cell migration can be determined using the transwell migration assay.

For the application of the compounds of the present invention as anti-inflammatory agents in vivo it is preferable to use the pure (S)-enantiomer of the compound, rather than the racemic mixture of the two enantiomers or the pure (R)-enantiomer.
Claims

1. Use of a compound of general formula (I) or a pharmaceutically acceptable salt thereof, for the preparation of a medicament intended to treat an inflammatory disorder:

![Chemical Structure](image)

(I)

wherein

X is \(-\text{CO-Y-}(\text{R}^1)_{n}\) or \(\text{SO}_2-\text{Y-}(\text{R}^1)_{n}\);

Y is a cycloalkyl or polycycloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group);

or is a cycloalkenyl or polycycloalkenyl group;

each \(\text{R}^1\) is independently selected from hydrogen or an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radical of 1 to 20 carbon atoms (for example of 5 to 20 carbon atoms, of 8 to 20 carbon atoms, of 9 to 20 carbon atoms, of 10 to 18 carbon atoms, of 12 to 18 carbon atoms, of 13 to 18 carbon atoms, of 14 to 18 carbon atoms, of 13 to 17 carbon atoms);

or each \(\text{R}^1\) is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radical; and

n is any integer from 1 to m, where m is the maximum number of substitutions permissible on the cyclo-group Y; or

alternatively \(\text{R}^1\) is selected from a peptido radical having from 1 to 4 peptidic moieties linked together by peptide bonds.

2. Use of a compound of formula (I') or a pharmaceutically acceptable salt thereof, for the preparation of a medicament intended to treat an inflammatory disorder:
wherein X has the same meaning as above.

3. A pharmaceutical composition comprising, as active ingredient, a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient and/or carrier:

(II)

wherein

X is \(-\text{CO-Y-}(R^1)_{\text{n}}\) or \(\text{SO}_2-\text{Y-}(R^1)_{\text{n}}\);

Y is a cycloalkyl or polycycloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group);

or is a cycloalkenyl or polycycloalkenyl group;

each R^1 is independently selected from hydrogen or an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radical of 1 to 20 carbon atoms (for example of 5 to 20 carbon atoms, of 8 to 20 carbon atoms, of 9 to 20 carbon atoms, of 10 to 18 carbon atoms, of 12 to 18 carbon atoms, of 13 to 18 carbon atoms, of 14 to 18 carbon atoms, of 13 to 17 carbon atoms);

or each R^1 is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radical; and
n is any integer from 1 to m, where m is the maximum number of substitutions permissible on the cyclo-group Y; or

alternatively R¹ is selected from a peptido radical having from 1 to 4 peptic moieties linked together by peptide bonds (for example a peptido radical of 1 to 4 amino acid residues).

4. A pharmaceutically acceptable composition comprising active ingredient, a compound of formula (I') or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient and/or carrier:

![Chemical Structure](I')

wherein X has the same meaning as above.

5. A compound of general formula (I):

![Chemical Structure](I)

wherein

X is \(-\text{CO-}Y-(R¹)ₙ\) or \(\text{SO}_₂-Y-(R¹)ₙ\);

Y is a cycloalkyl or polycycloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group);

or is a cycloalkenyl or polycycloalkenyl group;

each R¹ is independently selected from hydrogen or an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radical of 1 to 20 carbon atoms (for example
of 5 to 20 carbon atoms, of 8 to 20 carbon atoms, of 9 to 20 carbon atoms, of 10 to 18 carbon atoms, of 12 to 18 carbon atoms, of 13 to 18 carbon atoms, of 14 to 18 carbon atoms, of 13 to 17 carbon atoms);

or each R¹ is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminokalkyl or aminodialkyl radical; and

n is any integer from 1 to m, where m is the maximum number of substitutions permissible on the cyclo-group Y; or

alternatively R¹ is selected from a peptido radical having from 1 to 4 peptidic moieties linked together by peptide bonds.

6. A compound of general formula (I'):

![Diagram of compound (I')]  

wherein X has the same meaning as above.

7. Compounds, compositions and uses of the compounds of general formula (I) or (I'), or their pharmaceutically acceptable salts, according to any preceding claim, wherein the ring or rings of Y constrain the bond angles at the alpha-carbon to be essentially tetrahedral (i.e. sp3 hybrid bonds).

8. A use according to claim 1 or a pharmaceutical composition according to claim 3, or a compound according to claim 5, wherein the compound is selected from the group consisting of:

- (S)-3-(Cyclohexanecarbonyl) amino-caprolactam;
- (S)-3-(1'-methylcyclohexanecarbonyl) amino-caprolactam;
- (S)-3-(Cyclohex-1'-ene) carbonyl) amino-caprolactam;
- (S)-3-(trans-4'-pentylicyclohexane-1-carbonyl) amino-caprolactam;
- (S)-3-(4'-penty1[2,2,2]bicyclo-octane-1-carbonyl)amino-caprolactam;

- (S)-3-(1'-Adamantanecarbonyl)amino-caprolactam;

-(S)-3-(1'-Adamantanylmethanecarbonyl)amino-caprolactam;

- (S)-3-(3'-chloro-1'-adamantanecarbonyl)amino-caprolactam;

- (S)-3-(3',5'-Dimethyl-1'-adamantanecarbonyl)amino-caprolactam;

- (S)-3-(3',5',7'-Trimethyl-1'-adamantanecarbonyl)amino-caprolactam;

and sulfonyle analogues thereof;

and pharmaceutically acceptable salts thereof.

9. A use according to claim 1 or pharmaceutical composition according to claim 3, or a compound according to claim 5 wherein the compound is (S)-3-(1'-Adamantanecarbonyl)amino-caprolactam and pharmaceutically acceptable salts thereof.

10. Use of a compound of formula (I) or (I') according to one of claims 1, 2, 8 and 9 wherein the inflammatory disorder is selected from the group consisting of autoimmune diseases, vascular disorders, viral infection or replication, asthma, osteoporosis (low bone mineral density), tumor growth, rheumatoid arthritis, organ transplant rejection and/or delayed graft or organ function, a disorder characterised by an elevated TNF-α level, psoriasis, skin wounds, disorders caused by intracellular parasites, allergies, Alzheimer's disease, antigen induced recall response, immune response suppression, multiple sclerosis, ALS, fibrosis, and formation of adhesions.

11. A method of treatment, amelioration or prophylaxis of the symptoms of an inflammatory disease (including an adverse inflammatory reaction to any agent) by the administration to a patient of an anti-inflammatory amount of a compound, composition or medicament as claimed in any of claims 1 to 9.

12. Compounds, compositions, and uses of the compounds of general formula (I) or (I'), or their pharmaceutically acceptable salts, or a method of treatment according to any preceding claim wherein the substituent R¹ is not a straight chain alkyl group.
13. Compounds, compositions, and uses of the compounds of general formula (I) or (I'), or their pharmaceutically acceptable salts, or a method of treatment according to any preceding claim wherein the substituent R¹ is a branched chain alkyl group.

14. Compounds, compositions, and uses of the compounds of general formula (I) or (I'), or their pharmaceutically acceptable salts, or a method of treatment according to any preceding claim wherein the substituent R¹ is not an alkyl group.
Figure 1
A. CLASSIFICATION OF SUBJECT MATTER

A61K31/55  A61P29/00  C07D233/10

According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K  A61P  C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data, EMBASE, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>MENAJDENKO, V. G. ET AL: &quot;Synthesis and the keto-enol equilibrium of 2-acyl lactams&quot; RUSSIAN CHEMICAL BULLETIN (TRANSLATION OF IZVESTIYA AKADEMII NAUK, SERIYA KHIMICHESKAYA), 52(11), 2473–2482 CODEN: RCBUEY; ISSN: 1066-5285, 2003, XP008058593 Compound 32 the whole document</td>
<td>5, 7, 12, 14</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C

Patient family members are listed in annex

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claimed(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority data and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

18 January 2006

Date of mailing of the international search report

26/01/2006

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HJ Rijswijk
Tel (+31-70) 340-2040, Tx 31 651 epo nl
Fax (+31-70) 340-3010

Authorized officer

A. Jakobs
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
</table>
INTERNATIONAL SEARCH REPORT

Box II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
   - because they relate to subject matter not required to be searched by this Authority, namely:
     - Although claim 11 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
   - because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
   - because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2004)
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>JP 2003146972 A</td>
<td>21-05-2003</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 1416683 A</td>
<td>10-11-1983</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 8302389 A</td>
<td>10-01-1984</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CS 8303146 A2</td>
<td>13-06-1985</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 3217373 A1</td>
<td>10-11-1983</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 204883 A</td>
<td>09-11-1983</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 8402579 A1</td>
<td>01-05-1984</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI 831549 A</td>
<td>09-11-1983</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 78556 A1</td>
<td>27-09-1984</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 191833 B</td>
<td>28-04-1987</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 58208274 A</td>
<td>03-12-1983</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 204136 A</td>
<td>31-05-1985</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PH 20414 A</td>
<td>05-01-1987</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PL 241836 A1</td>
<td>11-02-1986</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 4468392 A</td>
<td>28-08-1984</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 8303234 A</td>
<td>29-08-1984</td>
</tr>
</tbody>
</table>